AlloSource earns laser etching patent: 3 notes

Written by Shayna Korol | December 04, 2018 | Print  |

AlloSource received a U.S. patent for its proprietary method to create ProChondrixCR, the company's fresh cryopreserved osteochondral allograft.  

Here are three things to know:

1. The patent, titled "Enclosure for laser cutting of human tissue," includes AlloSource's process of producing a closed system that allows a laser beam to pass through and etch allograft tissue while maintaining a sterile barrier.

2. The method is designed to expedite processing, maximize tissue use and allow for the use of a specialized laser technology in a clean room setting.

3. ProChondrixCR is a cartilage restoration therapy. "Laser etching stimulates the cartilage regenerative system while the graft replaces the missing cartilage in superficial defects down to the bone level," said AlloSource Senior Medical Director Ross Wilkins, MD.

More articles on biologics:
4 things to know about Bio2 Technologies
Spine biologics market to reach $2.72B by 2025 — 3 things to know
Vail-Summit Orthopaedics uses injectable treatments, biologics to expand care: 3 notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months